CyDex, Inc. Licenses Captisol(R) to Proteolix, Inc. for Promising Oncology Compound

Published: May 01, 2007

LENEXA, Kan.--(BUSINESS WIRE)--CyDex, Inc., a specialty pharmaceutical company developing improved products through innovative drug delivery, today announced an agreement licensing its Captisol® enabling technology to Proteolix, Inc. for use with a proteasome inhibitor that has shown promise in treating certain cancers such as multiple myeloma and mantle cell lymphoma.

Back to news